Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > attention deficit hyperactivity disorder market
Get a free sample of Attention Deficit Hyperactivity Disorder Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
Get a free sample of Attention Deficit Hyperactivity Disorder Market
Your inquiry has been received. Our team will reach out to you with the required details via email. To ensure that you don't miss their response, kindly remember to check your spam folder as well!
Form submitted successfully!
Error submitting form. Please try again.
The rising diagnosis rates of attention deficit hyperactivity disorder are a key driver in the industry development. The increasing awareness among parents and healthcare professionals, combined with improved diagnostic tools, has led to a surge in ADHD diagnoses. Moreover, the increase in the number of public health campaigns and educational programs has also played a role in destigmatizing ADHD, prompting more individuals to seek diagnosis and treatment. This growth is further increased by advancements in digital health, which facilitate easier access to healthcare professionals, and the development of more effective pharmacological treatments.
The stimulants segment dominated the market with USD 11.2 billion in 2023, as these medications are highly effective, with approximately 70-80% of patients responding positively.
The global attention deficit hyperactivity disorder industry was valued at USD 15.8 billion in 2023 and is estimated to grow at a 5.1% CAGR from 2024 to 2032, driven by the rising global prevalence of ADHD and advancements in diagnostic technologies.
U.S. ADHD market is expected to grow at a 5.1% CAGR, reaching USD 10.2 billion by 2032, supported by high awareness and diagnosis rates, along with a strong focus on both medication and behavioral therapy sectors.
Key players in the industry include Aytu BioPharma, Eli Lilly and Company, Ironshore, Janssen Pharmaceuticals, Lupin, Mallinckrodt, Novartis, and Pfizer.